CACaption Management, LLC
Institutional investor · Portfolio as of Q1 2019
Top Holdings540 positions
CELGENE CORP | 531,600 | $50.2M | 2.8% | — | — | — | First report — |
BRISTOL-MYERS SQUIBB CO | 997,200 | $47.6M | 2.6% | — | — | — | First report — |
DISNEY WALT CO | 290,400 | $32.2M | 1.8% | — | — | — | First report — |
BOEING CO | 76,600 | $29.2M | 1.6% | — | — | — | First report — |
Tapestry Inc | 864,000 | $28.1M | 1.5% | — | — | — | First report — |
BRISTOL-MYERS SQUIBB CO | 498,500 | $23.8M | 1.3% | — | — | — | First report — |
TARGA RES CORP | 552,100 | $22.9M | 1.3% | — | — | — | First report — |
NOVAVAX INC | 2M | $22.3M | 1.2% | — | — | — | First report — |
WAGEWORKS INC | 550,500 | $20.8M | 1.1% | — | — | — | First report — |
BOEING CO | 50,000 | $19.1M | 1.1% | — | — | — | First report — |
Tapestry Inc | 580,000 | $18.8M | 1.0% | $27.18 | 0.00% | 1 qtr | First report 0 |
ASCENDIS PHARMA A/S | 153,800 | $18.1M | 1.0% | — | — | — | First report — |
Union Pacific Corporation | 100,000 | $16.7M | 0.9% | — | — | — | First report — |
ZIMMER BIOMET HOLDINGS INC | 130,000 | $16.6M | 0.9% | — | — | — | First report — |
PAPA JOHNS INTL INC COM | 293,200 | $15.5M | 0.9% | — | — | — | First report — |
CENTENE CORP DEL | 270,000 | $14.3M | 0.8% | — | — | — | First report — |
CELGENE CORP | 149,100 | $14.1M | 0.8% | — | — | — | First report — |
MEDICINES CO | 494,900 | $13.8M | 0.8% | — | — | — | First report — |
EXACT SCIENCES CORP | 158,800 | $13.8M | 0.8% | — | — | — | First report — |
PG&E CORP | 758,500 | $13.5M | 0.7% | — | — | — | First report — |
Caption Management, LLC manages $1.8B across 540 positions as of Q1 2019. Top holdings: CELG puts (2.8%), BMY calls (2.6%), DIS calls (1.8%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1/5.0.
First quarter we have for this fund: 540 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $1.8B across 540 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR